Ilse Hoffman

Prof. Dr. Ilse Hoffman


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2011 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
IHIlse Hoffman
Ilse Hoffman
JTJ. Tack
J. Tack

24 April 2009 in Neurogastroenterology & Motility
Verified
Journal Article
Closed access
PDF file
IHIlse Hoffman
Ilse Hoffman
RVR. Vos
R. Vos
JTJ. Tack
J. Tack

6 August 2024 in Children
Verified
Journal Article
Open access
PDF file
FVFemke De Vleeschhauwer
Femke De Vleeschhauwer
KCKristina Casteels
Kristina Casteels
IHIlse Hoffman
Ilse Hoffman
MPMarijke Proesmans
Marijke Proesmans
ARAnne M. Rochtus
Anne M. Rochtus
Topical corticosteroids are a mainstay in the treatment of many pediatric disorders. While they have proven beneficial therapeutic effects and are generally considered safe, systemic adverse events may occur. This study presents four cases of children who experienced systemic adverse events after using inhaled and intranasal topical corticosteroids, as well as topical corticosteroids in other forms. A comprehensive literature review was performed to explore the existing evidence on this topic. The aim of this study is to raise awareness among healthcare providers about the possibility of systemic adverse events associated with the use of locally administered corticosteroids in pediatric patients. This information underscores the importance of careful monitoring, individualized treatment plans, and further research to better understand and mitigate the risks associated with corticosteroids, even those not given systemically.

11 June 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
LNLisa Nuyttens
Lisa Nuyttens
TDToon Dominicus
Toon Dominicus
CKCheyenne Keppens
Cheyenne Keppens
TATine Alliet
Tine Alliet
SVSophie Verelst
Sophie Verelst
DBDominique MA Bullens
Dominique MA Bullens
Background: Eosinophilic esophagitis is a chronic immune-mediated disease with increasing prevalence. In pediatric populations, it often coexists with IgE-mediated food sensitization. This dual diagnosis presents unique therapeutic challenges, including on the one hand both temporary and lifelong dietary restrictions, and on the other hand, therapeutic interventions with a potential impact on quality of life (QoL). Objectives: This study prospectively evaluated the prevalence of IgE-mediated food sensitization and allergy in children with EoE attending a tertiary center in Flanders, Belgium. Additionally, it prospectively documented dietary habits and restrictions in these children, with or without concomitant IgE-mediated food allergies, and assessed the impact of dietary management on quality of life compared to pharmacological treatment. Methods: We consecutively followed 30 children with biopsy-confirmed pediatric EoE (PedEoE) attending a tertiary referral center for at least 12 months. Patient demographics, allergy testing, dietary history, and treatment modalities were recorded. Symptom score and PedEoE QoL were assessed using validated Pediatric Eosinophilic Esophagitis Symptom Score (PEESS 2.0) and Pediatric Quality of Life Inventory (PedsQL 3.0) questionnaires. Statistical analysis was performed using the Mann–Whitney U test and Kruskal–Wallis test with Dunn’s test as a post hoc test. Results: Among 30 children with EoE (60% male, median age 8 years), 60 PedEoE QoL (PedsQL) and 39 symptom (PEESS) questionnaires were collected at one or more time points over a median follow-up of 14.5 months. IgE sensitization to common dietary triggers was observed in multiple patients, with varying clinical reactivity. Symptom scores tended to be higher in children without histological remission, though differences were not statistically significant (median PEESS 23.75 vs. 17.50, p = 0.1934). Grouped by degree of dietary restriction, QoL scores showed significant differences (child p = 0.0102; parent p = 0.0203), with children in the 1–2 food elimination group reporting better QoL compared to the 0 food elimination and >6 food elimination groups. No clear statistically significant differences were observed between the 1–2 food elimination group and the 3–4 or 5–6 food elimination groups. Conclusions: IgE sensitization is prevalent among pediatric EoE patients and has significant clinical implications for disease management. Treatment choice can influence not only disease control but also the QoL of both patients and their families.

22 April 2026 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
ISIsabelle Scheers
Isabelle Scheers
GSGiulia Sonnino
Giulia Sonnino
GRGeert 11761447140 Roeyen
Geert 11761447140 Roeyen
FBFrederik Berrevoet
Frederik Berrevoet
MDMYRIAM DELHAYE
MYRIAM DELHAYE
PDPierre H. Deprez
Pierre H. Deprez

30 June 2017
Verified
Book Chapter
Closed access
PDF file
IHIlse Hoffman
Ilse Hoffman